



*Press Release*

## **Ondansetron Hydrochloride Tablets**

**Contact:**

Suzanne Collier  
Marketing Communications  
(888) TEVA USA

### **Teva Introduces Ondansetron Hydrochloride Tablets**

**North Wales, Pennsylvania, July 10, 2007** – Teva Pharmaceuticals is pleased to announce the introduction and availability of Ondansetron Hydrochloride Tablets. This product is AB rated and bioequivalent to Zofran®\* Tablets. Ondansetron Hydrochloride Tablets are available in 4 mg and 8 mg, both in bottle sizes of 30 and 3 x 1 blister packs.

“Our customers count on Teva for a continuous supply of new generic products,” states John Denman, V.P. Sales and Marketing. “With the launch of Ondansetron Hydrochloride Tablets we add another quality product to our broad line of affordable generic pharmaceuticals.”

Teva Pharmaceuticals, located in North Wales, Pennsylvania, is the leading pharmaceutical manufacturer for both new and total prescriptions.‡ The company has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry.‡

\* Zofran® is a registered trademark of Glaxo Group Ltd.

‡ Data on file, Teva USA.

Please see accompanying prescribing information.

**Administrative Offices:**

1090 Horsham Road, P.O. Box 1090, North Wales, PA 19454-1090  
Phone: 215.591.3000 Fax: 215.591.8600 [www.tevausea.com](http://www.tevausea.com)